Frontiers in Oncology (Dec 2023)

Corrigendum: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

  • Yezhe Cheng,
  • Xiaoxi Yuan,
  • Qiang Tian,
  • Xiuying Huang,
  • Yang Chen,
  • Yuzhi Pu,
  • Hu Long,
  • Mingyu Xu,
  • Yafei Ji,
  • Jia Xie,
  • Yuping Tan,
  • Xi Zhao,
  • Hongmei Song

DOI
https://doi.org/10.3389/fonc.2023.1334938
Journal volume & issue
Vol. 13

Abstract

Read online

No abstracts available.

Keywords